FPH - Fisher Paykel Healthcare.

[alokdhir]

NICE already had a negative recommendation for HFNO of F&P , now they have given conditional recommendation for CPAP over HFNO while acknowledging the difficulties both at patient level and at hospital level with CPAP ventilation . Only negative is that F&P expected to get positive recommendation for its HFNO which they didn't get ...but still its being seen as beneficial as it is alternative to CPAP ventilation due to patient and hospital reasons .

CPAP is much more difficult on the patient as its much more uncomfortable . Also hospitals need better trained staff for administering it while having both choices available .

Though some CPAP consumables are produced by F&P too .

On the whole not the result F&P wanted as their HFNO didn't get thumbs up as all thought but should not effect them too much .

$ 34 to $ 31 is overreaction IMHO ....CONSOLIDATION CONTINUES !

"The number of organisations who have published evidence based guidelines recommending the use of NHF for COVID-19 patients continues to grow:

• World Health Organisation
• National Institutes of Health
• National Health Commission of the Peoples Republic of China
• Surviving Sepsis Campaign
• Australia and New Zealand Intensive Care Society
• European Respiratory Society
• International expert consensus statement
• Expert recommendations from a French panel consisting of members from various intensive care societies "

From F&P website ...they have many positive recommendations too

[BlackPeter]

While it might be interesting to discuss the daily ripple of price movements, at the end of the day it is as consequential as discussing the ripples in the ocean when dealing with the impact of climate change ...

Just looked at a 10 year chart of FPH (and yes, I used a log-scale) ... and it appears that Covid provided a bit of tailwind for the FPH price (lifting it above the red mean line). It appears as well that SP development did now drop back to the mean ... i.e. we are exactly back to pre-Covid SP growth. Obviously - there may or may not follow some sort of undershoot.

FPH decade.jpg

However - in my view no need to worry about the daily share price jitter (unless you are a trader).

PS: Sorry you need to turn your head to fully appreciate the graph. No idea why the forum SW choose to flip the graph by 90 degrees

[alokdhir]

While it might be interesting to discuss the daily ripple of price movements, at the end of the day it is as consequential as discussing the ripples in the ocean when dealing with the impact of climate change ...

Just looked at a 10 year chart of FPH (and yes, I used a log-scale) ... and it appears that Covid provided a bit of tailwind for the FPH price (lifting it above the red mean line). It appears as well that SP development did now drop back to the mean ... i.e. we are exactly back to pre-Covid SP growth. Obviously - there may or may not follow some sort of undershoot.

FPH decade.jpg

However - in my view no need to worry about the daily share price jitter (unless you are a trader).

PS: Sorry you need to turn your head to fully appreciate the graph. No idea why the forum SW choose to flip the graph by 90 degrees

Fully agree ...great time to invest for the long term ...it should follow its long term trend UP

[Rawz]

While it might be interesting to discuss the daily ripple of price movements, at the end of the day it is as consequential as discussing the ripples in the ocean when dealing with the impact of climate change ...

Just looked at a 10 year chart of FPH (and yes, I used a log-scale) ... and it appears that Covid provided a bit of tailwind for the FPH price (lifting it above the red mean line). It appears as well that SP development did now drop back to the mean ... i.e. we are exactly back to pre-Covid SP growth. Obviously - there may or may not follow some sort of undershoot.

FPH decade.jpg

However - in my view no need to worry about the daily share price jitter (unless you are a trader).

PS: Sorry you need to turn your head to fully appreciate the graph. No idea why the forum SW choose to flip the graph by 90 degrees

I think you if are new to investing or worried about the current share price movements, this post by BlackPeter is a perfect reminder to think long term on these type of stocks with incredible track records.

So go on, load that chart and have a look. It's worth the sore neck

[kiora]

"Does Fisher Paykel make CPAP machines?
The F&P ICON+ Auto is the fully featured Auto CPAP which combines all of Fisher & Paykel Healthcare's leading clinical technologies including our advanced auto-adjusting algorithm and SensAwake Technology."
"Homecare: CPAP Devices
F&P SleepStyle™Latest
F&P SleepStyle™
HC150
HC150 Humidifier
Product Code: HC150

ICON+ AutoSupported
ICON™+ Auto

https://www.fphcare.com/us/products/.../cpap-devices/

[alokdhir]

"Does Fisher Paykel make CPAP machines?
The F&P ICON+ Auto is the fully featured Auto CPAP which combines all of Fisher & Paykel Healthcare's leading clinical technologies including our advanced auto-adjusting algorithm and SensAwake Technology."
"Homecare: CPAP Devices
F&P SleepStyle™Latest
F&P SleepStyle™
HC150
HC150 Humidifier
Product Code: HC150

ICON+ AutoSupported
ICON™+ Auto

https://www.fphcare.com/us/products/.../cpap-devices/

Recent recommendation of NICE is about CPAP in hospital setting and that too in favour of famed F&P 's HFNO therapy ...simple words using CPAP non invasive therapy over Nasal High Flow Therapy of F&P for standard covid patients in hospitals requiring ventilation support to help with respiratory discomfort or insufficiency

They do have CPAP machines for OSA for home use

[Jaa]

Stock Takes: What's behind Fisher & Paykel's sinking share price?

16 Sep, 2021

By: Tamsyn Parker

Fisher & Paykel Healthcare's recent share price weakness is being blamed on a change in recommendations for Covid treatment out of the United Kingdom.

The UK's National Institute for Health and Care Excellence (NICE) indicated CPAP therapy should be the standard care for Covid patients rather than Fisher & Paykel's high-flow nasal oxygen (HFNO).

The findings were based on two controlled trials conducted in the midst of the UK's Covid pandemic which found CPAP therapy reduces the need for intubation in Covid-19 patients but HFNO does not provide any benefit over standard low-flow oxygen therapy.

JP Morgan analysis on the issue noted this was a "surprising and disappointing result for F&P". But said at this stage they did not expect clinical guideline in other jurisdictions to follow the UK's lead until the results of the trial were peer reviewed and published.

"The peer view process is likely to help clarify some concerns with the results including whether the relatively high rate of cross-over between the therapy groups or the lack of a clear protocol for escalating patients to intubation was likely to have had any bearing on the results."

JP Morgan estimate the impact on sales to the UK by F&P as a result of the change in guidance will only be small.

"We estimate sales for the UK account around 4 per cent of F&P's pre-Covid revenues from consumables for the humidification of ventilate patients. Given the small size of UK revenues and the fact the previous NICE guidelines recommended against HFNO for Covid patients, we believe the latest alert is unlikely to have a material impact on group earnings."

Harbour Asset Management's Shane Solly said the situation suggested there could be a bit more consolidation to come in F&P's share price.

"It's more raising a question than saying the treatment is no longer valid." But still he said investors had to take the issue seriously.

Very interesting, thanks for posting.

I will just note that while UK may only be 4% of revenues in itself, it's health recommendations are very influential and could impact global demand.

[alokdhir]

[QUOTE=Jaa;910634]Very interesting, thanks for posting.

I will just note that while UK may only be 4% of revenues in itself, it's health recommendations are very influential and could impact global demand.[/QUOTE

"Given the small size of UK revenues and the fact the previous NICE guidelines recommended against HFNO for Covid patients, we believe the latest alert is unlikely to have a material impact on group earnings."

Hope that clarifies ....IMO it can be seen small positive that new guidelines are not against HFNO but as second choice

[Jaa]

[QUOTE=alokdhir;910649]

Very interesting, thanks for posting.

I will just note that while UK may only be 4% of revenues in itself, it's health recommendations are very influential and could impact global demand.[/QUOTE

"Given the small size of UK revenues and the fact the previous NICE guidelines recommended against HFNO for Covid patients, we believe the latest alert is unlikely to have a material impact on group earnings."

Hope that clarifies ....IMO it can be seen small positive that new guidelines are not against HFNO but as second choice

I took "HFNO does not provide any benefit over standard low-flow oxygen therapy" as don't use it not use it as a second choice?

[alokdhir]

[QUOTE=Jaa;910657]

I took "HFNO does not provide any benefit over standard low-flow oxygen therapy" as don't use it not use it as a second choice?

Thats what their random actual user trials have come out with that HFNO has marginal or no advantage over regular hospital oxygen but CPAP helps better but they have noted in their recommendation that CPAP is not easily tolerated by patients also needs advanced training to hospital staff so NHS hospitals can offer both choices where ever feasible , can use HFNO to wean away from CPAP , during meal breaks and also on fatigue of helmet type masks etc . Also note from NICE website that these new updates to their recommendation are dated 2nd Sept 2021 .

Here to add that there are many other reputable institutions recommending HFNO for Covid respiratory support including WHO